Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -250%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.15, delivering a surprise of 40%.Over the last four quarters, the company has surpassed cons ...

Company Performance - Hawkins reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.74 per share, and up from $0.66 per share a year ago, representing an earnings surprise of 5.41% [1] - The company posted revenues of $245.32 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.62%, compared to $223.02 million in the same quarter last year [2] - Over the last four quarters, Hawkins has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Future Outlook - The sustainability of Hawkins' stock price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.34 on revenues of $268.31 million, and for the current fiscal year, it is $4.54 on revenues of $1.05 billion [7] - The estimate revisions trend for Hawkins is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Chemical - Specialty industry, to which Hawkins belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can materially affect stock performance [5][8]

分组1 - Steris reported quarterly earnings of $2.74 per share, exceeding the Zacks Consensus Estimate of $2.59 per share, and up from $2.41 per share a year ago, representing an earnings surprise of 5.79% [1][2] - The company posted revenues of $1.48 billion for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.09%, and compared to $1.42 billion in the same quarter last year [2] - Over the last four quarters, Steris has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] 分组2 - Steris shares have increased approximately 12.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4][6] - The current consensus EPS estimate for the upcoming quarter is $2.32 on revenues of $1.36 billion, and for the current fiscal year, it is $9.94 on revenues of $5.78 billion [7] 分组3 - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Company Performance - ScPharmaceuticals reported a quarterly loss of $0.34 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of -25.93% [1] - The company posted revenues of $11.75 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.67%, compared to revenues of $6.1 million a year ago [2] - Over the last four quarters, ScPharmaceuticals has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Movement and Outlook - ScPharmaceuticals shares have declined approximately 34.5% since the beginning of the year, while the S&P 500 has gained 0.1% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $16.95 million, and for the current fiscal year, it is -$1.03 on revenues of $76.42 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which ScPharmaceuticals belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact ScPharmaceuticals' stock performance [5][6]

Core Insights - ARS Pharmaceuticals, Inc. reported a quarterly loss of $0.35 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.11 per share a year ago [1] - The company posted revenues of $7.97 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.03%, and this is a significant increase from zero revenues a year ago [2] - The stock has increased approximately 26.5% since the beginning of the year, outperforming the S&P 500's gain of 0.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $15.45 million, and for the current fiscal year, it is -$1.28 on revenues of $89.27 million [7] - The estimate revisions trend for ARS Pharmaceuticals is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which ARS Pharmaceuticals belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, ProPhase Labs, Inc., is expected to report a quarterly loss of $0.18 per share, reflecting a year-over-year change of -157.1% [9]

Core Viewpoint - Kolibri Global Energy Inc. reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, and showing an increase from $0.09 per share a year ago, indicating a positive earnings surprise of 23.08% [1][2] Financial Performance - The company achieved revenues of $16.37 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.97% and up from $14.29 million in the same quarter last year [2] - Over the last four quarters, Kolibri Global Energy has exceeded consensus EPS estimates three times [2] Stock Performance - Kolibri Global Energy shares have increased approximately 16.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.1% [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, with current consensus EPS estimates at $0.14 for the upcoming quarter and $0.66 for the current fiscal year [4][7] - The estimate revisions trend for Kolibri Global Energy is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Alternative Energy - Other industry, to which Kolibri Global Energy belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Performance - M-tron Industries, Inc. reported quarterly earnings of $0.56 per share, missing the Zacks Consensus Estimate of $0.66 per share, but showing an increase from $0.53 per share a year ago, resulting in an earnings surprise of -15.15% [1] - The company posted revenues of $12.73 million for the quarter ended March 2025, which was 2.06% below the Zacks Consensus Estimate, but an increase from $11.19 million year-over-year [2] - Over the last four quarters, M-tron Industries has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - M-tron Industries shares have increased approximately 18.5% since the beginning of the year, contrasting with a -0.6% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.66 on revenues of $13.2 million, and for the current fiscal year, it is $2.72 on revenues of $53.7 million [7] Industry Outlook - The Engineering - R and D Services industry, to which M-tron Industries belongs, is currently ranked in the top 9% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact M-tron Industries' stock performance [5][6]

分组1 - ClearPoint Neuro, Inc. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, representing an earnings surprise of -46.67% [1] - The company posted revenues of $8.49 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.85%, and showing an increase from $7.64 million in the same quarter last year [2] - ClearPoint Neuro has surpassed consensus revenue estimates three times over the last four quarters, while it has only surpassed consensus EPS estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 11.3% since the beginning of the year compared to the S&P 500's decline of -0.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.16 on revenues of $9.2 million, and for the current fiscal year, it is -$0.62 on revenues of $38.95 million [7] - The Medical - Instruments industry, to which ClearPoint Neuro belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Over the last four quarters, the company has surpassed consensus EPS estimates three times. Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 28.57%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produ ...

Company Performance - Hyperfine, Inc. reported a quarterly loss of $0.12 per share, which aligns with the Zacks Consensus Estimate, and is an improvement from a loss of $0.14 per share a year ago [1] - The company posted revenues of $2.14 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 27.07%, compared to revenues of $3.3 million in the same quarter last year [2] - Over the last four quarters, Hyperfine has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2][3] Stock Outlook - Hyperfine shares have declined approximately 17.1% since the beginning of the year, contrasting with the S&P 500's decline of 0.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.11 on revenues of $3.09 million, and for the current fiscal year, it is -$0.45 on revenues of $15.59 million [7] Industry Context - The Medical - Instruments industry, to which Hyperfine belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]